Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide QT/QTc Study in CRPC
NCT02578797Phase 1Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Aragon Pharmaceuticals. Primary endpoint: QTc Fridericia parameter. Started Dec 2015; status: completed.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02578797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578797.